Pediatrix Medical Group (NYSE:MD) Now Covered by Macquarie

Macquarie assumed coverage on shares of Pediatrix Medical Group (NYSE:MD) in a research note released on Monday, MarketBeat.com reports. The firm issued an outperform rating and a $18.00 price target on the stock.

Several other equities analysts have also recently weighed in on MD. Jefferies Financial Group increased their price objective on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft raised their target price on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Truist Financial upped their price objective on Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Mizuho boosted their target price on Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research report on Tuesday, November 19th. Finally, StockNews.com raised Pediatrix Medical Group from a “hold” rating to a “buy” rating in a research note on Wednesday, December 11th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $16.42.

Pediatrix Medical Group Price Performance

Shares of MD stock opened at $14.46 on Monday. The company has a quick ratio of 1.42, a current ratio of 1.42 and a debt-to-equity ratio of 0.83. The business’s fifty day moving average is $14.02 and its 200 day moving average is $10.83. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of -4.73, a PEG ratio of 2.00 and a beta of 1.57. Pediatrix Medical Group has a twelve month low of $6.62 and a twelve month high of $16.41.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings results on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.07. The firm had revenue of $511.20 million during the quarter, compared to the consensus estimate of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The company’s revenue was up .9% on a year-over-year basis. During the same period last year, the company earned $0.29 earnings per share. Research analysts expect that Pediatrix Medical Group will post 1.26 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Mary Ann E. Moore sold 8,108 shares of the stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $16.00, for a total value of $129,728.00. Following the completion of the transaction, the executive vice president now directly owns 135,810 shares of the company’s stock, valued at $2,172,960. This trade represents a 5.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Mark S. Ordan sold 27,600 shares of the company’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total value of $423,660.00. Following the completion of the transaction, the director now directly owns 138,683 shares in the company, valued at approximately $2,128,784.05. The trade was a 16.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Pediatrix Medical Group

A number of large investors have recently bought and sold shares of MD. Rubric Capital Management LP lifted its stake in shares of Pediatrix Medical Group by 1.5% in the 3rd quarter. Rubric Capital Management LP now owns 8,275,000 shares of the company’s stock valued at $95,907,000 after purchasing an additional 125,000 shares during the period. State Street Corp raised its holdings in shares of Pediatrix Medical Group by 1.4% during the third quarter. State Street Corp now owns 3,540,791 shares of the company’s stock valued at $41,038,000 after acquiring an additional 50,597 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Pediatrix Medical Group by 2.4% in the third quarter. Geode Capital Management LLC now owns 1,936,751 shares of the company’s stock valued at $22,452,000 after acquiring an additional 45,155 shares in the last quarter. Dana Investment Advisors Inc. boosted its stake in shares of Pediatrix Medical Group by 80.3% in the second quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock worth $7,725,000 after acquiring an additional 455,785 shares during the last quarter. Finally, Weiss Asset Management LP boosted its stake in shares of Pediatrix Medical Group by 50.5% in the third quarter. Weiss Asset Management LP now owns 912,818 shares of the company’s stock worth $10,580,000 after acquiring an additional 306,143 shares during the last quarter. Hedge funds and other institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.